HC Wainwright Has Weak Forecast for Precigen FY2026 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Stock analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for Precigen in a research note issued to investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of ($0.01) per share for the year, down from their prior estimate of $0.01. HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.20 EPS and FY2029 earnings at $0.62 EPS.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of Precigen in a research note on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, Precigen currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $1.39 on Friday. The business’s 50 day moving average is $0.94 and its two-hundred day moving average is $1.06. Precigen has a 1-year low of $0.65 and a 1-year high of $1.93. The stock has a market capitalization of $407.09 million, a P/E ratio of -2.53 and a beta of 1.65.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Traphagen Investment Advisors LLC bought a new position in Precigen in the third quarter worth approximately $29,000. Stifel Financial Corp grew its stake in Precigen by 94.9% in the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 15,680 shares in the last quarter. SG Americas Securities LLC grew its stake in Precigen by 44.2% in the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 13,823 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Precigen by 86.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 25,681 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in Precigen by 56.7% in the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 18,097 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.